Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Cytopathology : Official Journal of the British Society for Clinical Cytology|April 16, 2002
Interlaboratory reproducibility of the immunocytochemical assessment of oestrogen and progesterone receptors and proliferative activity in fine needle aspiration of breast cancerM Confortini, F Carozzi, L Bozzola, et al.
Oncology|January 1, 1980
Immunologic monitoring during combined radiochemoimmunotherapy in inoperable lung cancerE Sega, M Rinaldi, M Mottolese, et al.
The American Journal of Pathology|April 6, 2001
c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findingsA Biroccio, B Benassi, I D'Agnano, et al.
Oncology|April 15, 2010
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapiesAlessandra Fabi, G Metro, A Di Benedetto, et al.
Journal of the American College of Surgeons|May 9, 2000
Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic studyC Botti, B Pescatore, M Mottolese, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 23, 1997
Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinomaC L Maini, A Tofani, R Sciuto, et al.
Cancer Investigation|December 9, 2009
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapyG Metro, Z Zheng, A Fabi, et al.
International Journal of Cancer|November 24, 1999
Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patientsP Nisticò, M Mottolese, S Cascioli, et al.
Oncogene|May 12, 2015
hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cellsP Trono, F Di Modugno, R Circo, et al.
Cell Death & Disease|August 7, 2015
Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancerG Sette, V Salvati, M Mottolese, et al.
Pageof 10